Generate a tailored SOP for Dr. Benjamin Ebert. Improve your application with a focused, well-structured draft.
Ebert laboratory focuses on the molecular basis of treatment for hematologic malignancies, with a particular focus on myelodysplastic syndromes (MDS). Through large-scale genetic analyses of patient samples, the lab has identified somatic mutations that predict prognosis and response to therapies in MDS patients. It has characterized the pre-malignant state of hematopoietic cells and explored the molecular ontogeny of genetic lesions in myeloid malignancies. In addition to human genetic studies, the lab has elucidated the biological basis for the transformation of hematopoietic cells by somatic mutations and developed novel in vivo models to study myeloid malignancies. The lab employs genetic and small molecule screens to identify novel therapeutic targets for small molecule treatments of hematologic malignancies and sickle cell disease. Moreover, the Ebert lab has investigated the mechanism of action of lenalidomide, a derivative of thalidomide, which modulates the function of the E3 ubiquitin ligase, inducing drug-dependent degradation of specific substrates essential for the survival of multiple myeloma and MDS cells, representing a class of drugs that bind and modulate the function of the E3 ubiquitin ligase.
Administered by the Harvard Kenneth C. Griffin Graduate School of Arts and Sciences (GSAS).